Filing summary: AcelRx Pharmaceuticals, Inc. — Q1 2018
Entity discrepancy: The request identifies TALPHERA, INC., but the supplied 10-Q is for AcelRx Pharmaceuticals, Inc. This summary reflects the filing provided, not a Talphera filing.
Business context and reporting period
The filing covers the three months ended March 31, 2018. AcelRx is a specialty pharmaceutical company developing acute-pain therapies. Its principal candidates are DSUVIA (known as DZUVEO outside the U.S.) and Zalviso; Zalviso is marketed in Europe by partner Grünenthal. The financial statements are unaudited.
Key financial metrics
| Metric | Q1 2018 | Q1 2017 / prior date |
|---|---|---|
| Total revenue | $0.343 million | $3.109 million |
| Cost of goods sold | $1.114 million | $4.125 million |
| Gross loss (revenue less cost of goods sold) | $0.771 million | $1.016 million |
| Research and development | $3.513 million | $6.919 million |
| General and administrative | $3.985 million | $4.138 million |
| Operating loss | $8.269 million | $12.073 million |
| Net loss | $11.592 million | $15.551 million |
| Basic and diluted loss per share | $0.23 | $0.34 |
| Cash, cash equivalents and short-term investments | $51.176 million at March 31 | $60.469 million at December 31, 2017 |
| Net cash used in operating activities | $7.374 million | $7.535 million |
At March 31, 2018, total assets were $65.8 million, total liabilities $112.7 million, and stockholders’ deficit $46.9 million. Hercules debt was $17.4 million, including accrued end-of-term fee; scheduled maturity is March 2020. The separate liability for monetized future royalties was $86.4 million. The company reported an accumulated deficit of $309.5 million.
Material changes versus the prior comparable period
- Revenue fell by $2.766 million, primarily because Grünenthal product sales were much lower than in Q1 2017. Management said partner sales growth may not translate into AcelRx product revenue immediately as Grünenthal draws down inventory; it expected collaboration revenue to decline in 2018 before a possible increase in 2019.
- Cost of goods sold declined 73%, but AcelRx still reported a gross loss. Management expected negative gross margins on Zalviso deliveries for the foreseeable future, citing low volumes and transfer prices that do not recover indirect manufacturing costs.
- R&D expense fell 49%, mainly because the Zalviso IAP312 study had been completed in 2017. Lower operating expenses contributed to the reduced net loss.
- Operating cash use was broadly similar year over year. Cash and investments declined $9.3 million from year-end, reflecting operations and $1.9 million of debt payments.
Outlook, commentary and risks
- DSUVIA: The FDA had issued a Complete Response Letter in October 2017, requesting additional safety information and revised use instructions validated by a human-factors study. The company reported completing that study in April 2018 and resubmitting the NDA in May, after the quarter. It anticipated a six-month FDA review and a PDUFA date in Q4 2018; approval was not assured.
- DZUVEO: In April 2018, the EMA’s CHMP adopted a positive opinion. A European Commission decision was anticipated in Q3 2018, after the quarter.
- Zalviso: The company planned to resubmit its U.S. NDA in the second half of 2018, supported by the IAP312 study. The FDA could still require additional work or limit any approved indication.
- Liquidity: Management estimated existing capital would fund operations through at least the end of Q2 2019, based on its current plan. It also said resources likely would not fund operations until sustainable revenue is achieved; additional financing may be needed and may not be available on acceptable terms.
- Funding and obligations: AcelRx expects continued losses and negative operating cash flows. PDL receives most specified European Zalviso royalties and a portion of early commercial milestones under the royalty monetization, while imputed non-cash interest on that liability was $2.816 million in Q1; management forecast approximately $12 million of such expense for full-year 2018.
- Key execution risks: Regulatory outcomes and timing for both candidates; opioid-related controls and potential REMS; commercial adoption and reimbursement; dependence on Grünenthal and third-party manufacturers; limited qualified supply sources; and the need to raise capital. The DoD extended its DSUVIA contract through February 2019 and added $0.5 million in services.
- The company reported no material legal proceedings, no defaults on senior securities, and effective disclosure controls and procedures.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is AcelRx’s, not Talphera’s.
- Check subsequent FDA and European regulatory decisions against the Q4 2018 and Q3 2018 targets stated in this filing.
- Assess cash burn and financing needs against management’s stated runway through at least Q2 2019.
- Track Grünenthal’s Zalviso sales, inventory drawdown, AcelRx’s supply economics, and the effect of the PDL royalty-sharing arrangement.
- Review the Hercules loan terms, scheduled payments, maturity, and security; distinguish the $17.4 million loan balance from the $86.4 million royalty-monetization liability.